SHARING IDEAS THAT DO GOOD

Aussie biotech addressing sepsis with new diagnostic

post-image
Australian company Microbio has been awarded a Federal Government Accelerating Commercialisation Grant to commercialise a new diagnostic assay to rapidly identify 26 of the most common pathogens that cause bloodstream infections and sepsis. The InfectID-Blood Stream Infection (BSI) diagnostic assay is a real-time Polymerase Chain Reaction (PCR) identifies the pathogen causing the infection in about two hours to enable patients to be treated with targeted antimicrobials in a timely manner. Sepsis kills around 11 million people around the world each year. | https://microbio.com.au/news-and-events/ 
What do you think?

You must be logged in to post a comment.
Comments

Related Posts

Healthcare

post-image

Innovation in safe drinking water
28 November 2021 by Lynn Wood 3 Comments
 

Healthcare

post-image

Science edges closer to an Alzheimer's vaccine
19 November 2021 by Phil Wolffe 0 Comments

Healthcare

post-image

Digitising Critical Event Management is the business priority for 2022
16 November 2021 by Ashleigh Duff 0 Comments